GlassScriptPhysician profile
Curtis L Jansen
NPI 1447530597
$2,262.69
in general payments reported to CMS, 2019-2025
26 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.14 · 2020: $15.66 · 2021: $138 · 2022: $251 · 2023: $88.40 · 2024: $755 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,828 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,828.27 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $466.35 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $277.53 | 2024-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $186.07 | 2021-2024 | |
| Lundbeck LLC | $182.79 | 2024-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $161.47 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.36 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $91.21 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $86.49 | 2022-2023 | Xarelto |
| Lilly USA, LLC | $73.61 | 2024-2025 | Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $61.55 | 2022-2023 | Verquvo |
| Pfizer INC. | $61.20 | 2022 | |
| Abbvie INC. | $57.32 | 2025 | |
| Insulet Corporation | $54.97 | 2025 | Omnipod |
| Viatris Specialty LLC | $51.81 | 2025 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $49.24 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $46.41 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $39.91 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $32.43 | 2025 | Shingrix, Arexvy, Bexsero |
| Vertex Pharmaceuticals Incorporated | $29.54 | 2025 | |
| Exact Sciences Corporation | $24.16 | 2024 | Cologuard Collection Kit |
| Phadia US INC. | $24.00 | 2025 | Immunocap |
| Abbott Laboratories | $23.63 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $18.69 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $14.61 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $13.20 | 2023 | Caldolor |
| Amgen INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Jansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.